Personalized Neurology
- 1 March 2005
- journal article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 2 (1) , 15-21
- https://doi.org/10.1517/17410541.2.1.15
Abstract
Personalized medicine simply means the prescription of specific therapeutics best suited for an individual based on pharmacogenetic and pharmacogenomic information. It involves integration of molecular diagnostics with therapeutics. Selection of a suitable medicine from various approaches available based on optimal efficacy and safety in an individual patient will be preferable to trial-and-error approaches. A personalized approach will improve the management of neurological disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, neuropathic pain, and migraine. Gene therapy and RNA interference will facilitate the development of personalized treatment for neurological disorders. It is anticipated that several components of this system will be in place by the year 2010 and it will be a part of neurological practice by the year 2015. However, not all neurological disorders would require a personalized approach.Keywords
This publication has 17 references indexed in Scilit:
- Malic Enzyme 2 May Underlie Susceptibility to Adolescent-Onset Idiopathic Generalized EpilepsyAmerican Journal of Human Genetics, 2005
- Molecular basis for catecholaminergic neuron diversityProceedings of the National Academy of Sciences, 2004
- No Mutations in CACNA1A and ATP1A2 in Probands With Common Types of MigraineArchives of Neurology, 2004
- Génétique des complications du diabète : neuropathie périphériqueAnnales d'Endocrinologie, 2004
- Functional Genomics, Fragile X Syndrome, and RNA InterferenceArchives of Neurology, 2003
- Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1New England Journal of Medicine, 2003
- Is Refractory Epilepsy Due to Genetically Determined Resistance to Antiepileptic Drugs?New England Journal of Medicine, 2003
- Nanodiagnostics: application of nanotechnology in molecular diagnosticsExpert Review of Molecular Diagnostics, 2003
- A novel mechanism underlying drug resistance in chronic epilepsyAnnals of Neurology, 2003
- Genotyping of CYP2D6 in Parkinsons's Diseasecclm, 2000